negative breast cancers demonstrate elevated nuclear NF-κB expression and activity compared to luminal subtypes with or without HER2/ErbB2 amplification. [4] [5] [6] It is widely accepted that the IKK-IκB axis regulates canonical NF-κB activation. In quiescent cells, NF-κB transcription factors are sequestered in the cytoplasm through physical association with inhibitors of NF-κB (IκB) proteins. Extracellular stimuli, including pro-inflammatory cytokines, induce phosphorylation of IκB kinases (IKK), which then phosphorylate IκB proteins and trigger their dissociation via ubiquitination-mediated degradation. Degradation of IκB releases NF-κB transcription factors and promotes their nuclear translocation to initiate various transcription programs, including those that stimulate inflammation, proliferation, epithelial-to-mesenchymal transition (EMT), therapeutic resistance and self-renewal. [6] [7] [8] [9] [10] [11] [12] [13] Numerous regulators of the NF-κB system have been identified and here we focus on two signaling factors with potential functional interaction: the NF-κB interacting long non-coding RNA (NKILA) and enhancer of zeste homolog 2 (EZH2).
Nuclear factor-kappa B activity is augmented under the action of EZH2, a histone methyltransferase and transcriptional repressor displaying elevated and non-canonical transactivation activity in several cancers. [14] [15] [16] [17] In the canonical pathway, EZH2 acts as the catalytic subunit of the polycomb repressive complex 2 (PRC2) and prevents gene expression by methylating histone H3 on lysine 27.
In breast cancer, EZH2 acts independently of PRC2 and exerts dual functions in the presence or absence of oestrogen receptor (ER). In ER + cells, EZH2 physically associates with ERα and β-catenin to acti-
vate Wnt signaling and cell cycle progression by increasing cyclin D4
and c-Myc expression. 18 In the absence of ER, EZH2 interacts with the NF-κB system components RelA and RelB to potentiate NF-κB transcriptional activity, leading to inflammation, self-renewal and adoption of a tumour initiating cell (TIC) phenotype. [19] [20] [21] Moreover, EZH2 over-expression is associated with high-grade tumours enriched in TICs, and it has been suggested that EZH2 expression favours the transition of dormant progenitors or differentiated cells into an aggressive stem cell-like phenotype. [22] [23] [24] Preclinical studies of EZH2 inhibitors show promise in improving cancer status, and drugs such as tazemetostat (Epizyme) are currently being explored in Phase I and II clinical trials.
The anti-tumoural role of NKILA, a cytoplasmic NF-κB interacting long non-coding RNA, has been recently demonstrated in multiple cancers, including those of the breast. [25] [26] [27] Here, we elucidate the NF-κB/NKILA pathway in relation to EZH2, an immediate regulator of NF-κB activity in cancer cells. Upon challenge by pro-inflammatory cytokines, NKILA is transcriptionally activated by NF-κB signaling and suppresses further NF-κB activity by physically masking IKK-mediated IκB phosphorylation. The importance of this negative feedback loop was demonstrated in breast epithelial cells, where NKILA was shown to prevent constitutive activation of the NF-κB pathway under pro-inflammatory conditions. Consistent with its anti-tumoural function, low NKILA expression is associated with breast cancer metastasis and poor patient prognosis. 25 While EZH2
is known to promiscuously bind lncRNAs through its cooperation in the PRC2 complex, the existence of direct interaction between EZH2 and NKILA remains to be elucidated. Epithelial Growth Supplement (MEGS) (Gibco, S0155), 10% FBS and 0.01mg/ml human recombinant insulin. All media were passed through vacuum filtration and were protected from contamination by adding 1X Anti-Anti (antibiotic-antimycotic) (Gibco). Cells were grown at 37°C at 5% CO2 in T-75 and T-150 vent flasks. Media was changed routinely, and cells were passaged using 0.25% Trypsin-EDTA (1X) (Gibco). To respectively inhibit EZH2/1 or EZH2 methyltransferase function, 5μM UNC1999 (Cell Signaling Technology) or 5 μmol/L tazemetostat (Selleck Chemicals) were prepared in cell line-specific media and administered to 80%-90% confluent flasks for 48 hours.
BAY11-7082 inhibitor compound prepared in respective cell media (5 μmol/L) was administered for 24 hours to diminish NF-κB activity. NKILA was inhibited by transfection of microRNA 103 using Lipofectamine RNAiMAX Reagent, per manufacturer protocol.
| Transwell migration and invasion assays
Cell monolayers were dissociated with Trypsin, re-suspended in respective media containing 2% FBS with and without UNC1999 Treatments were performed in quadruplicate (n = 4) and tested for statistical significance using one-way ANOVA on Graphpad Prism 7.
| Cell count assay
HMEC, MCF-7 and MDA-MB-231 cells were seeded in triplicate significance by two-way ANOVA using GraphPad Prism 7.
| Cell lysate preparation and western blotting
Cell lysates were prepared using Cell Lysis Buffer (Cell Signaling Technology), supplemented with Phosphatase Inhibitor Cocktail 3 (Sigma) and Protease Inhibitor Cocktail (Sigma). Lysis buffer (1 mL)
was added to a confluent T-75 flask and cells were scraped off and and N-Cadherin (1:1000) primary antibodies were purchased from
Abcam while EZH1 (1:1000) antibody was purchased from Novus Biologicals.
| Quantitative analysis of NKILA transcript
Total RNA was extracted from fresh cell cultures using PureLink RNA Mini Kit (Invitrogen). NKILA cDNA template was prepared using NKILA and 18S ribosomal subunit universal control primer mixes, in addition to Taqman master mix, were purchased from Applied
Biosystems. Assays were performed using the ABI 7900HT system and transcript amplification results were generated using SDS 2.4
software. NKILA FAM reporter (ID:Hs04937740_s1) was normalized to 18S control (ID:Hs99999901_s1) across technical triplicates.
Taqman assays were repeated a minimum of 2-3 times for each cell line per treatment condition. Statistical significance was determined by one-way ANOVA or Student's t test as appropriate using Graphpad Prism 7.
| Receptor tyrosine kinase signaling antibody array kit
A PathScan Antibody Array Kit (Cell Signaling Technology) was used to detect receptor tyrosine kinase (RTK) activation and signaling.
The array employs an antibody capture mechanism for activated RTK molecules and downstream partners. The array was placed on glass slides and the immuno-dot-blot procedure was performed according to manufacture protocol. A volume of 150 μL (1 μg/μL) of cell lysate was incubated overnight at 4°C with each of the arrays.
After three consecutive washes, a volume of 150 μL of 1X biotinylated detection antibody cocktail was added to each well and arrays were incubated on an orbital shaker for 1 hour. To reveal the immuno-complexes, 150 μL 1X HRP-linked streptavidin was added to each well and incubated at room temperature for 30 minutes.
After three subsequent washes, the chemiluminescence agent, LumiGLO, was added onto the arrays and images were captured at varying exposure times using a Biorad imager. Each biomarker was represented in the array by a pair of dot-blots. Spot density analysis was performed using ImageJ software and the average dot density was plotted (n = 2).
| RE SULTS

| Homeostatic expression of EZH2 and NF-κB is inversely associated with NKILA transcription and correlates with metastatic potential
We evaluated homeostatic levels of nuclear NF-κB, NKILA and Relative expression of NF-κB and (B) EZH2 in nuclear lysates was measured by western blot using β-actin as a loading control, followed by densitometry analysis of bands (n = 3). (C) Relative NKILA transcript levels were measured by quantitative real time polymerase chain reaction using 18S rRNA as an endogenous control (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA EZH2 and H3K27 methylation in both breast cancer cell lines. In contrast, partial silencing of NKILA in HMECs reduced EZH2 levels and stimulated EZH2-independent H3K27 methylation ( Figure 2C ).
As inhibition of EZH2/1 and EZH2-only elicited diametric effects on NKILA expression in the two breast cancer cell lines, we explored the potential contribution of EZH1 to these cell-specific events. While overall levels of EZH1 were higher in HMECs and MDA-MB-231 cells, EZH1 levels were more sensitive to EZH2 inhibition in the ER + breast cancer cell line ( Figure 2D ).
| Pharmacological inhibition of NF-κB alters homeostatic levels of NKILA and EZH2 in a celldependent manner
Next, we investigated the effects of nuclear NF-κB depletion on NKILA homeostasis by treating cells with BAY11-7082, an inhibitor of IκBα phosphorylation and NF-κB nuclear translocation.
Inhibition of NF-κB significantly increased NKILA transcript levels in HMECs but had no effect on the two breast cancer cell lines ( Figure 3A) . We further examined the effects of NF-κB inhibition on endogenous EZH2 expression and its methyltransferase activity. Silencing NF-κB reduced EZH2 expression levels in both breast cancer cell lines, whereas the opposite effect was observed in
HMECs. Inhibition of NF-κB in the noncancerous cell line induced higher EZH2 expression and dramatically increased H3K27 methylation activity ( Figure 3B ).
| Fluctuations in EZH2/NKILA/NF-κB signaling lead to functional EMT remodelling
We next investigated whether fluctuations in EZH2 expression functionally contribute to enhanced motility and invasiveness by measuring cell migration and invasion following EZH2/1 silencing. Inhibition of EZH2/1 significantly blunted MDA-MB-231 cell migration and invasion but had no observed effect on the motility of HMECs and MCF-7 cells (Figure 4A and B) . 
| Pharmacological inhibition of NF-κB, but not EZH2 alters cell proliferation in a growth factordependent context
To determine whether fluctuations in NF-κB and EZH2 influence cell proliferation, we assayed 5-bromo-2'-deoxyuridine incorporation as a surrogate for measuring active cell division. Inhibition of NF-κB significantly increased HMEC proliferation but had no appreciable effect on either breast cancer cell line. In contrast, EZH2-only or EZH2/1 inhibition showed no significant effect on reducing cell proliferation in any of the three cell lines ( Figure 5 ).
| Inhibition of EZH2 contributes to cell fate response via nuclear NF-κB depletion
We further evaluated the effect of EZH2 inhibition on NF-κB-mediated cell cycle progression and cell fate determination. Using immunofluorescence staining and confocal laser scanning microscopy, we confirmed that EZH2/1 inhibition reduced nuclear NF-κB localization ( Figure 6A ). Next, we measured the expression of cell fate and cell cycle markers following EZH2 inhibition and subsequent NF-κB restriction. As EZH2 is known to drive cell fate via ER-dependent Wnt/β-catenin signaling, we anticipated the most robust response to EZH2 inhibition in the ER + MCF-7 cells.
Indeed, this appeared the case, as inhibition of EZH2/1 significantly decreased CDK4 expression and increased Akt phosphorylation, with the greatest effect observed in MCF-7 cells ( Figure 6B ).
Intriguingly, while all three cell lines experienced a reduction in CDK4 levels, no change to Cyclin D1 expression was observed.
Based on these observations, we propose a signaling mechanism involving EZH2/NF-κB-mediated progression of cell cycle and downstream fate determination ( Figure 6C ). HMECs, further confirming crosstalk between NF-κB homeostasis and growth factor-dependent cell cycle regulation ( Figure 7B ). Based on these results, we suggest a growth factor-dependent mechanism for endogenous regulation of cell fate and migration by the EZH2/ NF-κB/NKILA signaling axis ( Figure 7C ).
| D ISCUSS I ON
The potential for interfering crosstalk among multiple regulators of NF-κB signaling remains largely unexplored. Here, we investigated the interaction between EZH2 and the NF-κB/NKILA signaling axis in a non-tumourigenic breast epithelial cell line and in two breast cancer cell lines displaying differential hormone receptor expression.
Our evaluation of homeostatic levels of EZH2, NF-κB and NKILA corresponds to expression levels established in previous studies of breast cancer cell lines and patient-derived tumours. Constitutive activation of NF-κB and EZH2 overexpression have been documented in highly aggressive breast carcinomas and are correlated with clinico-pathological features. [28] [29] [30] [31] [32] In contrast, breast cancer cell lines demonstrating high metastatic potential possess low levels of NKILA transcript, consistent with its suggested anti-tumoural function. 25 We anticipated and observed an inverse association between EZH2 expression and NKILA transcript levels, with respective high/ low expression in breast cancer cells characterized by constitutively active NF-κB and high EZH2 expression.
We confirmed the interdependence of EZH2, NF-κB and NKILA
by demonstrating significant and cell-specific fluctuations in their expression following respective silencing of each signaling factor.
As EZH1 is known to exert compensatory H3K27 methylation under EZH2 knockdown, we employed the use of an EZH2-specific inhibitor and a nonspecific inhibitor to EZH2/1. 33 EZH2/1 inhibition reduced nuclear NF-κB expression, with the greatest reduction observed in ER + breast cancer cells. The potentiated effect in these cells may be explained by ER α -mediated mutual repression of NF-κB, as both EZH2 and NF-κB are known to interact directly with ER α . 34 We observed opposing effects of EZH2 and EZH2/1 inhibition on NKILA expression among the three cell lines, suggesting direct and differential NKILA regulation by EZH2 and EZH1. EZH2-spe- Other groups have observed potentially deleterious effects of EZH2 inhibition on promoting transcriptional instability, EMT, and irreversible epigenetic reprogramming. [44] [45] [46] By elucidating how EZH2
modulates the NF-κB/NKILA mechanism, we identify cell-intrinsic and systemic host elements that drive NF-κB-mediated imbalances, ultimately contributing to noncancerous cell transformation. Finally, this work supports future investigation into the EZH2/NF-κB/ NKILA signaling axis as a potential biomarker panel for monitoring therapeutic resistance under EZH2 inhibitor delivery, in addition to screening for personalized treatment regimens.
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